Effect of Integrated, Person-Centred Palliative Advanced Home and Heart Failure Care on NT-proBNP Levels: A Substudy of the PREFER Study

• 作者: Fryxell Jenni Olofsson Mona Brännström Margareta Boman Kurt
• 来源期刊: 心血管病(英文)
• 学科: 医学
• 关键词: Chronic Heart Failure Palliative Care Integrated Care NT-PROBNP ELDERLY
• 年，卷（期）: 2021,（1）
• 页码范围: 1-10
• 页数: 10页
• 分类号: R54

摘要

<strong>Objective:</strong><span style="font-family:;" "=""><span style="font-family:Verdana;"> In 2012, we initiated a new person-centred model, integrated </span><b><span style="font-family:Verdana;">P</span></b><span style="font-family:Verdana;">alliative advanced home ca</span><b><span style="font-family:Verdana;">RE</span></b><span style="font-family:Verdana;"> and heart </span><b><span style="font-family:Verdana;">F</span></b><span style="font-family:Verdana;">ailur</span><b><span style="font-family:Verdana;">E</span></b><span style="font-family:Verdana;"> ca</span><b><span style="font-family:Verdana;">R</span></b><span style="font-family:Verdana;">e (PREFER), to integrate specialised palliative home care with heart failure care. Natriuretic peptide</span></span><span style="font-family:Verdana;">-</span><span style="font-family:Verdana;">guided treatment is valuable for younger patients (age < 75 years), but its usefulness in palliative care is uncertain. We explored whether patients in PREFER reduced mean level of N-terminal pro B-type natriuretic peptide (NT-proBNP) more than the control group.</span><span style="font-family:Verdana;"> </span><b><span style="font-family:Verdana;">Design:</span></b><span style="font-family:Verdana;"> A pre-specified, exploratory substudy, analysed within the prospective, randomised PREFER study, which had an open, non-blinded design.</span><span style="font-family:Verdana;"> </span><b><span style="font-family:Verdana;">Participants:</span></b><span style="font-family:Verdana;"> Patients in palliative care with chronic heart failure, New York Heart Association class III-IV were randomly assigned to an intervention (n = 36;26 males, 10 females, mean age:</span><span style="font-family:Verdana;"> </span><span style="font-family:Verdana;">81</span><span style="font-family:Verdana;">.</span><span style="font-family:Verdana;">9 years) or control group (n = 36;25 males, 11 females, mean age:</span><span style="font-family:;" "=""></span><span style="font-family:Verdana;">76</spa